{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:22:01Z","timestamp":1793784121401,"version":"4.6.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["72104003"],"award-info":[{"award-number":["72104003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-025-00886-3","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T10:12:46Z","timestamp":1741601566000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparative safety signals of dopamine agonists: psychiatric and cardiovascular risks derived from FDA adverse event reporting system (FAERS) data"],"prefix":"10.1186","volume":"26","author":[{"given":"Li","family":"Mu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanmiao","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"key":"886_CR1","doi-asserted-by":"publisher","first-page":"108392","DOI":"10.1016\/j.pharmthera.2023.108392","volume":"245","author":"M Ferraiolo","year":"2023","unstructured":"Ferraiolo M, Hermans E. The complex molecular pharmacology of the dopamine D(2) receptor: implications for pramipexole, ropinirole, and rotigotine. Pharmacol Ther. 2023;245:108392. https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108392.","journal-title":"Pharmacol Ther"},{"issue":"3","key":"886_CR2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1517\/13543784.2014.869209","volume":"23","author":"F Blandini","year":"2014","unstructured":"Blandini F, Armentero MT. Dopamine receptor agonists for Parkinson\u2019s disease. Expert Opin Investig Drugs. 2014;23(3):387\u2013410. https:\/\/doi.org\/10.1517\/13543784.2014.869209.","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"886_CR3","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.2174\/1570159x20666220915091022","volume":"21","author":"XZ Jing","year":"2023","unstructured":"Jing XZ, Yang HJ, Taximaimaiti R, et al. Advances in the therapeutic use of non-ergot dopamine agonists in the treatment of motor and non-motor symptoms of Parkinson\u2019s disease. Curr Neuropharmacol. 2023;21(5):1224\u201340. https:\/\/doi.org\/10.2174\/1570159x20666220915091022.","journal-title":"Curr Neuropharmacol"},{"issue":"1","key":"886_CR4","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s42466-024-00325-4","volume":"6","author":"GA-O H\u00f6glinger","year":"2024","unstructured":"H\u00f6glinger GA-O, Trenkwalder C. Diagnosis and treatment of Parkinson\u00b4s disease (guideline of the German society for Neurology). Neurol Res Pract. 2024;6(1):30. https:\/\/doi.org\/10.1186\/s42466-024-00325-4.","journal-title":"Neurol Res Pract"},{"issue":"7","key":"886_CR5","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s40265-019-01103-2","volume":"79","author":"M Torti","year":"2019","unstructured":"Torti M, Bravi D, Vacca L, et al. Are all dopamine agonists essentially the same?? Drugs. 2019;79(7):693\u2013703. https:\/\/doi.org\/10.1007\/s40265-019-01103-2.","journal-title":"Drugs"},{"issue":"8","key":"886_CR6","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/mds.27372","volume":"33","author":"SH Fox","year":"2018","unstructured":"Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson\u2019s disease. Mov Disord. 2018;33(8):1248\u201366. https:\/\/doi.org\/10.1002\/mds.27372.","journal-title":"Mov Disord"},{"issue":"3","key":"886_CR7","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/ene.15635","volume":"30","author":"XT Chen","year":"2023","unstructured":"Chen XT, Zhang Q, Wen SY, et al. Efficacy and safety of non-ergot dopamine-receptor agonists as an adjunct to levodopa in advanced Parkinson\u2019s disease: A network meta-analysis. Eur J Neurol. 2023;30(3):762\u201373. https:\/\/doi.org\/10.1111\/ene.15635.","journal-title":"Eur J Neurol"},{"issue":"2","key":"886_CR8","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s11102-024-01383-2","volume":"27","author":"MH Almalki","year":"2024","unstructured":"Almalki MH, Alsuraikh MA, Almalki E, et al. Impulse control disorders in patients with dopamine agonist-treated pituitary adenomas: a cross-sectional multicenter study. Pituitary. 2024;27(2):197\u2013203. https:\/\/doi.org\/10.1007\/s11102-024-01383-2.","journal-title":"Pituitary"},{"issue":"1","key":"886_CR9","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s13311-021-01019-4","volume":"18","author":"TR Gossard","year":"2021","unstructured":"Gossard TR, Trotti LM, Videnovic A, et al. Restless legs syndrome: contemporary diagnosis and treatment. Neurotherapeutics. 2021;18(1):140\u201355. https:\/\/doi.org\/10.1007\/s13311-021-01019-4.","journal-title":"Neurotherapeutics"},{"issue":"1","key":"886_CR10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.sleep.2014.09.015","volume":"16","author":"J Zhang","year":"2015","unstructured":"Zhang J, Liu B, Zheng Y, et al. Pramipexole for Chinese people with primary restless legs syndrome: a 12-week multicenter, randomized, double-blind study. Sleep Med. 2015;16(1):181\u20135. https:\/\/doi.org\/10.1016\/j.sleep.2014.09.015.","journal-title":"Sleep Med"},{"issue":"6","key":"886_CR11","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s00702-023-02647-0","volume":"130","author":"D Woitalla","year":"2023","unstructured":"Woitalla D, Buhmann C, Hilker-Roggendorf R, et al. Role of dopamine agonists in Parkinson\u2019s disease therapy. J Neural Transm (Vienna). 2023;130(6):863\u201373. https:\/\/doi.org\/10.1007\/s00702-023-02647-0.","journal-title":"J Neural Transm (Vienna)"},{"key":"886_CR12","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.cca.2021.08.009","volume":"522","author":"S Latif","year":"2021","unstructured":"Latif S, Jahangeer M, Maknoon Razia D, et al. Dopamine in Parkinson\u2019s disease. Clin Chim Acta. 2021;522:114\u201326. https:\/\/doi.org\/10.1016\/j.cca.2021.08.009.","journal-title":"Clin Chim Acta"},{"key":"886_CR13","doi-asserted-by":"publisher","first-page":"1183823","DOI":"10.3389\/fneur.2023.1183823","volume":"14","author":"XT Chen","year":"2023","unstructured":"Chen XT, Zhang Q, Chen FF, et al. Comparative efficacy and safety of six non-ergot dopamine-receptor agonists in early Parkinson\u2019s disease: a systematic review and network meta-analysis. Front Neurol. 2023;14:1183823. https:\/\/doi.org\/10.3389\/fneur.2023.1183823.","journal-title":"Front Neurol"},{"issue":"4","key":"886_CR14","doi-asserted-by":"publisher","first-page":"e14531","DOI":"10.1111\/cns.14531","volume":"30","author":"W Li","year":"2024","unstructured":"Li W, Zhang H, Zhang Y, et al. Comparison of the effectiveness, safety, and costs of anti-Parkinson drugs: A multiple-center retrospective study. CNS Neurosci Ther. 2024;30(4):e14531. https:\/\/doi.org\/10.1111\/cns.14531.","journal-title":"CNS Neurosci Ther"},{"key":"886_CR15","doi-asserted-by":"publisher","first-page":"793361","DOI":"10.3389\/fphar.2021.793361","volume":"12","author":"ZM Yi","year":"2021","unstructured":"Yi ZM, Willis S, Zhang Y, et al. Impact of a collaborative pharmaceutical care service for patients with Parkinson\u2019s disease. Front Pharmacol. 2021;12:793361. https:\/\/doi.org\/10.3389\/fphar.2021.793361.","journal-title":"Front Pharmacol"},{"key":"886_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jad.2023.11.076","volume":"347","author":"H Zhu","year":"2024","unstructured":"Zhu H, Qu Y, Du Z, et al. Mining and analysis of adverse event signals of Cariprazine based on the real-world data of FAERS database. J Affect Disord. 2024;347:45\u201350. https:\/\/doi.org\/10.1016\/j.jad.2023.11.076.","journal-title":"J Affect Disord"},{"issue":"12","key":"886_CR17","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1002\/mds.23204","volume":"25","author":"S Perez-Lloret","year":"2010","unstructured":"Perez-Lloret S, Bondon-Guitton E, Rascol O, et al. Adverse drug reactions to dopamine agonists: a comparative study in the French pharmacovigilance database. Mov Disord. 2010;25(12):1876\u201380. https:\/\/doi.org\/10.1002\/mds.23204.","journal-title":"Mov Disord"},{"issue":"20","key":"886_CR18","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1111\/j.1744-7909.2011.01037.x","volume":"36","author":"Y Xiang","year":"2011","unstructured":"Xiang Y, Xie Y, Fau - Yi D, Yi D. [Pharmacovigilance of major parmaceutical innovation]. China J Chin Materia Med. 2011;36(20):2831. https:\/\/doi.org\/10.1111\/j.1744-7909.2011.01037.x.","journal-title":"China J Chin Materia Med"},{"issue":"21","key":"886_CR19","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.1002\/sim.2473","volume":"25","author":"GN Nor\u00e9n","year":"2006","unstructured":"Nor\u00e9n GN, Bate A, Fau - Orre R, Orre R, Fau - Edwards IR, et al. Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events. Stat Med. 2006;25(21):3740\u201357. https:\/\/doi.org\/10.1002\/sim.2473.","journal-title":"Stat Med"},{"issue":"11","key":"886_CR20","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/j.molp.2023.09.010","volume":"16","author":"C Chen","year":"2023","unstructured":"Chen C, Wu Y, Li J, et al. TBtools-II: A one for all, all for one bioinformatics platform for biological big-data mining. Mol Plant. 2023;16(11):1733\u201342. https:\/\/doi.org\/10.1016\/j.molp.2023.09.010.","journal-title":"Mol Plant"},{"issue":"12","key":"886_CR21","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/archneur.64.12.1721","volume":"64","author":"JC Corvol","year":"2007","unstructured":"Corvol JC, Anzouan-Kacou JB, Fauveau E, et al. Heart valve regurgitation, pergolide use, and Parkinson disease: an observational study and meta-analysis. Arch Neurol. 2007;64(12):1721\u20136. https:\/\/doi.org\/10.1001\/archneur.64.12.1721.","journal-title":"Arch Neurol"},{"key":"886_CR22","unstructured":"Hongjun L. Advances and concensus on erectile dysfunction. Chin J Hum Sexuality. 2011."},{"issue":"17","key":"886_CR23","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1021\/acschemneuro.0c00332","volume":"11","author":"SM Wilson","year":"2020","unstructured":"Wilson SM, Wurst MG, Whatley MF, et al. Classics in chemical neuroscience: Pramipexole. ACS Chem Neurosci. 2020;11(17):2506\u201312. https:\/\/doi.org\/10.1021\/acschemneuro.0c00332.","journal-title":"ACS Chem Neurosci"},{"issue":"4","key":"886_CR24","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.3390\/life13041043","volume":"13","author":"AA-OX Tundo","year":"2023","unstructured":"Tundo AA-OX, Betro SA-O, de Filippis RA-OX, et al. Pramipexole augmentation for Treatment-Resistant unipolar and bipolar depression in the real world: A systematic review and meta-analysis. Life (Basel). 2023;13(4):1043. https:\/\/doi.org\/10.3390\/life13041043.","journal-title":"Life (Basel)"},{"key":"886_CR25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1749-6632.2009.05149.x","volume":"1187","author":"CA Heidbreder","year":"2010","unstructured":"Heidbreder CA, Newman AH. Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders. Ann N Y Acad Sci. 2010;1187:4\u201334. https:\/\/doi.org\/10.1111\/j.1749-6632.2009.05149.x.","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"886_CR26","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1007\/s10072-023-07254-1","volume":"45","author":"LG Soileau","year":"2024","unstructured":"Soileau LG, Talbot NC, Storey NR, et al. Impulse control disorders in Parkinson\u2019s disease patients treated with pramipexole and ropinirole: a systematic review and meta-analysis. Neurol Sci. 2024;45(4):1399\u2013408. https:\/\/doi.org\/10.1007\/s10072-023-07254-1.","journal-title":"Neurol Sci"},{"issue":"7","key":"886_CR27","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s40263-019-00646-y","volume":"33","author":"JE Frampton","year":"2019","unstructured":"Frampton JE. Rotigotine transdermal patch: A review in Parkinson\u2019s disease. CNS Drugs. 2019;33(7):707\u201318. https:\/\/doi.org\/10.1007\/s40263-019-00646-y.","journal-title":"CNS Drugs"},{"issue":"2","key":"886_CR28","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40263-020-00788-4","volume":"35","author":"V Raeder","year":"2021","unstructured":"Raeder V, Boura I, Leta V, et al. Rotigotine transdermal patch for motor and non-motor Parkinson\u2019s disease: A review of 12 years\u2019 clinical experience. CNS Drugs. 2021;35(2):215\u201331. https:\/\/doi.org\/10.1007\/s40263-020-00788-4.","journal-title":"CNS Drugs"},{"issue":"8","key":"886_CR29","doi-asserted-by":"publisher","first-page":"102910","DOI":"10.1016\/j.arcmed.2023.102910","volume":"54","author":"R Hamblin","year":"2023","unstructured":"Hamblin R, Karavitaki N. Impulse control disorders in patients with pituitary tumors treated with dopamine agonists: A systematic review. Arch Med Res. 2023;54(8):102910. https:\/\/doi.org\/10.1016\/j.arcmed.2023.102910.","journal-title":"Arch Med Res"},{"issue":"1","key":"886_CR30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.slsci.2014.07.020","volume":"7","author":"DG T\u00e1vora","year":"2014","unstructured":"T\u00e1vora DG, de Bruin VM, Lopes Gama R, et al. The nature of excessive sleepiness and sudden sleep onset in Parkinson\u05f3s disease. Sleep Sci. 2014;7(1):13\u20138. https:\/\/doi.org\/10.1016\/j.slsci.2014.07.020.","journal-title":"Sleep Sci"},{"issue":"3","key":"886_CR31","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1124\/jpet.121.000719","volume":"380","author":"AP McCarthy","year":"2022","unstructured":"McCarthy AP, Svensson KA, Shanks E, et al. The dopamine D1 receptor positive allosteric modulator Mevidalen (LY3154207) enhances wakefulness in the humanized D1 mouse and in Sleep-Deprived healthy male volunteers. J Pharmacol Exp Ther. 2022;380(3):143\u201352. https:\/\/doi.org\/10.1124\/jpet.121.000719.","journal-title":"J Pharmacol Exp Ther"},{"key":"886_CR32","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.nbd.2013.10.029","volume":"63","author":"C Hyacinthe","year":"2014","unstructured":"Hyacinthe C, Barraud Q, Tison F, et al. D1 receptor agonist improves sleep-wake parameters in experimental parkinsonism. Neurobiol Dis. 2014;63:20\u20134. https:\/\/doi.org\/10.1016\/j.nbd.2013.10.029.","journal-title":"Neurobiol Dis"},{"key":"886_CR33","doi-asserted-by":"publisher","unstructured":"M\u00f6ller JC, Eggert Km Fau - Unger M, Unger M Fau - Odin P, et al. Clinical risk-benefit assessment of dopamine agonists. Eur J Neurol. 2008;15 Suppl 2:15\u201323. https:\/\/doi.org\/10.1111\/j.1468-1331.2008.02214.x","DOI":"10.1111\/j.1468-1331.2008.02214.x"},{"issue":"1","key":"886_CR34","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41531-023-00589-8","volume":"9","author":"WA-O Sako","year":"2023","unstructured":"Sako WA-O, Kogo YA-O, Koebis M, et al. Comparative efficacy and safety of adjunctive drugs to levodopa for fluctuating Parkinson\u2019s disease - network meta-analysis. NPJ Parkinsons Dis. 2023;9(1):143. https:\/\/doi.org\/10.1038\/s41531-023-00589-8.","journal-title":"NPJ Parkinsons Dis"},{"issue":"1","key":"886_CR35","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1586\/14737175.2.1.105","volume":"2","author":"C Singer","year":"2002","unstructured":"Singer C. Adverse effects in the treatment of Parkinson\u2019s disease. Expert Rev Neurother. 2002;2(1):105\u201318. https:\/\/doi.org\/10.1586\/14737175.2.1.105.","journal-title":"Expert Rev Neurother"},{"issue":"6","key":"886_CR36","doi-asserted-by":"publisher","first-page":"439","DOI":"10.2165\/00002018-200326060-00005","volume":"26","author":"M Etminan","year":"2003","unstructured":"Etminan M, Gill S, Fau - Samii A, Samii A. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson\u2019s disease: a meta-analysis. Drug Saf. 2003;26(6):439\u201344. https:\/\/doi.org\/10.2165\/00002018-200326060-00005.","journal-title":"Drug Saf"},{"issue":"6","key":"886_CR37","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1007\/s12325-019-00938-1","volume":"36","author":"H Zhao","year":"2019","unstructured":"Zhao H, Ning Y, Cooper J, et al. Indirect comparison of ropinirole and pramipexole as levodopa adjunctive therapy in advanced Parkinson\u2019s disease: A systematic review and network meta-analysis. Adv Ther. 2019;36(6):1252\u201365. https:\/\/doi.org\/10.1007\/s12325-019-00938-1.","journal-title":"Adv Ther"},{"issue":"6","key":"886_CR38","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S1474-4422(07)70108-4","volume":"6","author":"WH Poewe","year":"2007","unstructured":"Poewe WH, Rascol O, Fau - Quinn N, Quinn N, Fau - Tolosa E, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson\u2019s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. 2007;6(6):513\u201320. https:\/\/doi.org\/10.1016\/S1474-4422(07)70108-4.","journal-title":"Lancet Neurol"},{"issue":"1","key":"886_CR39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00702-015-1443-z","volume":"123","author":"I Csoti","year":"2016","unstructured":"Csoti I, Jost WH, Reichmann H. Parkinson\u2019s disease between internal medicine and neurology. J Neural Transm (Vienna). 2016;123(1):3\u201317. https:\/\/doi.org\/10.1007\/s00702-015-1443-z.","journal-title":"J Neural Transm (Vienna)"},{"issue":"1","key":"886_CR40","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1530\/eje-12-0121","volume":"167","author":"A Elenkova","year":"2012","unstructured":"Elenkova A, Shabani R, Kalinov K, et al. Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment. Eur J Endocrinol. 2012;167(1):17\u201325. https:\/\/doi.org\/10.1530\/eje-12-0121.","journal-title":"Eur J Endocrinol"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00886-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-00886-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00886-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T10:12:49Z","timestamp":1741601569000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-025-00886-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["886"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-00886-3","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,10]]},"assertion":[{"value":"4 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is not applicable since this study was based on publicly available anonymous data from the FDA Adverse Event Reporting System database ().","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable since this was a brief report presenting the secondary analysis of a large dataset.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"54"}}